Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: Results of a pilot study

Journal of Oncology Pharmacy Practice

Volumn 11, Issue 2, 2005, Pages 51-56

  Wiernikowski, John T ^a,b   Barr, R D ^a,b   Webber, C ^c   Guo, C Y ^b   Wright, M ^a,b   Atkinson, S A ^a,b  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Acute lymphoblastic leukaemia (ALL); Bisphosphonates; Morbidity; Osteopenia; Paediatrics; Quality of life

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; STEROID; TUMS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET SUPPLEMENTATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; MAINTENANCE THERAPY; MALE; MOTOR PERFORMANCE; NONHODGKIN LYMPHOMA; OSSIFICATION; OSTEOLYSIS; OUTCOMES RESEARCH; PARATHYROID HORMONE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; VITAMIN BLOOD LEVEL;

EID: 23644432064     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155205jp145oa     Document Type: Article

References (29)

1. Smith MA, Ries LAG. Childhood cancer: incidence, survival and mortality. In Pizzo PA, David DG eds. Principles and practice of pediatric oncololgy, fourth edition. Philadelphia, PA: Lippincott. Williams and Wilkins, 2002: 1-10.
2. Halton JM, Atkinson SA, Fraher L, et al. Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr 1995; 126: 557-64.
3. Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics 1999; 19: 873-75.
4. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996; 11: 1774-83.
5. Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf) 2002; 57: 185-91.
6. Crofton PM, Ahmed SF, Wade JC, et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998; 83: 3121-29.
7. Arguelles B, Barrios V, Pozo J, et al. Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal stndy. J Clin Endocrinol Metab 2000; 85: 4087-92.
8. Arikoski P, Komulainen J, Riikonen P, et al. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 1999; 14: 2002-2009.
9. Mul D, von Suijlekom-Smith LW, Tencate R, et al. Bone mineral density and body composition and influencing factors in children with rheumatic diseases treated with corticosteroids. J Pediatr Endocrinol Metab 2002; 15: 187-92.
10. Barr RD, Wright M, Wiernikowski J, et al. The effects of bisphosphonate therapy on the gross motor abilities of children with acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Med Pediatr Oncol 2003; 41: 252 [Abstract].
11. Suneja S, Barr RD, Upton S, Webber C. Bone mineral density in young adult survivors of acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol 2001; 23: A16 [Abstract 1173].
12. Glorieux F, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52.
13. Barr RD, Guo CY, Wiernikowski JT, et al. Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with pamidronate. Med Pediatr Oncol 2002; 39: 44-46.
14. Henderson RC, Lark RK, Kecshemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141: 644-51.
15. Langman CB, Thorson DK, Shaykin RA. Alendronate therapy in osteopenic pediatric disorders. Bone 1998; 23: S457.
16. Russell D, Rosenbaum P, Gowland C, et al. Gross motor function measure (GMFM): a measure of gross motor function in cerebral palsy. Hamilton, Ontario: McMaster University, 1990.
17. Bruininks R. Bruininks-Oseretsky test of motor proficiency. Circle Pines, MN: American Guidance Service, 1977.
18. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001; 33: 375-84.
19. Bischoff-Ferrari HA, Dietrich T, Orav J, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116: 634-39.
20. Samsa G, Edelman D, Rothman M, et al. Determining clinically important differences in health status measures. A general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-55.
21. Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics 1999; 19: 873-75.
22. Arikoski P, Komulainen J, Riikonen P, et al. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1 year prospective study. J Clin Endocrinol Metab 1999; 84: 3174-81.
23. Crofton PM, Ahmed SF, Wade JC, et al. Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res 2000; 48: 490-96.
24. Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999; 134: 264-67.
25. Othman F, Guo C-Y, Webber C, et al. Osteopenia in survivors of Wilms' tumor. Int J Oncol 2002; 20: 827-33.
26. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1988; 339: 292-99.
27. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum 1960-1966: 43: 200.
28. Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002; 29: 1786-92.
29. van Coeverden SCCM, Netelenbost JC, de Ridder CM, et al. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol 2002; 57: 107-16.